Innovative Vector System
· Engineered AAV vector
· Highly efficient delivery
· Tissue-specific targeting
· Lower immunogenicity
In-house Manufacturing
· Flexible commercial scale capability (up to 2,000L)
· Advanced & mature AD/PD capability
· Our gene therapy technologies are internally developed
Robust Pipeline
· Rare genetic diseases
· Chronic diseases
· Rich experience and data of investigator-initiated trial (IIT)
Media Center